Skip to main content

Schizophrenia

Center of Excellence

Leaders in the field sharing authoritative insights and institutional best practices.
INTERVIEW
Anticipate some significant changes in the treatment of schizophrenia over the next 10 years, from a move toward coordinated specialty care to harnessing the power of social media to help identify symptoms sooner, said John M. Kane, MD.
YOUR QUESTIONS ANSWERED
Is there any rationale for using both deutetrabenazine (Austedo) and valbenazine (Ingrezza) at the same time? Find out from Psych Congress cochair Rakesh Jain, MD, MPH.
YOUR QUESTIONS ANSWERED
Is there benefit in treating a patient with a VMAT2 inhibitor if they have already had severe tardive dyskinesia for several years? Find out here.
YOUR QUESTIONS ANSWERED
Are medications for tardive dyskinesia effective in mild, moderate, or severe cases? Get the answer from Psych Congress cochair Rakesh Jain, MD, MPH.
YOUR QUESTIONS ANSWERED
Ilan Melnick, MD, staff psychiatrist and chief medical officer, Passageway Residences of Dade County, Miami, Florida, answers questions about initiating long-acting injectable antipsychotics in patients.
Videos
Leslie Citrome, MD, MPH, discusses the link between schizophrenia and diabetes, the role of metabolic syndrome, weight gain from antipsychotics, and interventions for patients with schizophrenia.
YOUR QUESTIONS ANSWERED
Psych Congress Steering Committee member Vladimir Maletic, MD, MS, discusses whether inflammation has a role in the underpinnings of schizophrenia, and if anti-inflammatory treatments could have benefit.
Back to Top